What official sources establish

The care pathway continues while the implant remains in place.

FDA materials state that breast implants are not lifetime devices. Benefits, alternatives, device-specific risks, possible reoperation and continuing surveillance should be discussed in a structured manner; the implant identification card and operative records should remain available over the long term.

For asymptomatic silicone gel implants, current FDA recommendations identify ultrasound or MRI beginning five to six years after implantation and every two to three years thereafter. Symptoms or an equivocal ultrasound may require MRI. Implant-integrity surveillance does not replace ordinary breast screening or symptom-led assessment.

Transparency RegisterTR 07 · TR 06

Specialist interpretation

A device choice is also a continuity choice.

The review should consider not only shape, surface, fill and the immediate surgical plan, but also traceability, surveillance, future access to records, realistic reoperation scenarios and who will remain responsible after relocation or travel.

A manufacturer booklet or decision checklist supports informed discussion; it does not determine suitability for an individual’s anatomy or objective. The indication and long-term care system remain individual questions.

  • Review the current manufacturer-specific information, not only a generic brochure.
  • Retain the implant card, operative report and a durable digital copy.
  • Define who will monitor, evaluate symptoms and coordinate revision.
  • Consider future costs and access to surveillance and revision care before choosing the device.
Transparency RegisterTR 07 · TR 06

Limits

Surveillance data require careful interpretation.

Regulatory reporting and surveillance estimates can identify important safety signals, but they do not automatically provide comparable incidence rates between manufacturers or establish the best device for an individual patient. Those distinctions should remain explicit.

Transparency RegisterTR 07 · TR 06

Sources

Primary and authoritative references

  1. Breast Implants — Certain Labeling Recommendations to Improve Patient Communication

    U.S. Food and Drug Administration · 29 September 2020

    Official regulatory guidance; nonbinding guidance document.
  2. Risks and Complications of Breast Implants

    U.S. Food and Drug Administration · Updated 14 December 2023

    Official regulator information for patients and clinicians.
  3. Things to Consider Before Getting Breast Implants

    U.S. Food and Drug Administration · Current safety actions described from 27 October 2021

    Official patient guidance and U.S. labeling overview.
  4. Breast implant associated anaplastic large cell lymphoma (BIA-ALCL)

    UK Medicines and Healthcare products Regulatory Agency · Updated 11 December 2025

    Official surveillance guidance; reported rates should not be used for unsupported manufacturer comparison.